AWM
NBIX icon

Ariadne Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Ariadne Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,871
Closed -$222K – 231
2024
Q4 		$222K Buy
1,871
+215
+13% +$26.6K 0.1% 196
2024
Q3 		$205K Buy
+1,656
New +$227K 0.11% 193

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ariadne Wealth Management's NBIX Position: Q1 2025 in Review

Ariadne Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 1,871 shares — an estimated $222K sold.

Ariadne Wealth Management first reported a position in NBIX in Q3 2024 and held it in 2 quarters. The position peaked at $222K in Q4 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Ariadne Wealth Management reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Ariadne Wealth Management sold 1,871 Neurocrine Biosciences shares in Q1 2025, an estimated $222K.
  • Ariadne Wealth Management first reported a position in Neurocrine Biosciences in Q3 2024 and held it in 2 quarters.
  • Ariadne Wealth Management's Neurocrine Biosciences position peaked at $222K in Q4 2024.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Ariadne Wealth Management's 13F filing for Q1 2025, filed 13 May 2025.